Nemes Rush Group
VKTX icon

Nemes Rush Group’s Viking Therapeutics VKTX Stock Holding History

Nemes Rush Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$168K Hold
5,165
– – 0.01% 222
2026
Q2 		$201K Sell
5,165
-3
-0.1% -$97 0.02% 215
2026
Q1 		$168K Hold
5,168
– – 0.02% 227
2025
Q4 		$182K Buy
5,168
+68
+1% +$2.41K 0.02% 218
2025
Q3 		$134K Hold
5,100
– – 0.01% 233
2025
Q2 		$135K Hold
5,100
– – 0.01% 230
2025
Q1 		$123K Buy
5,100
+100
+2% +$3.16K 0.02% 238
2024
Q4 		$201K Hold
5,000
– – 0.02% 189
2024
Q3 		$410K Hold
5,000
– – 0.06% 124
2024
Q2 		$265K Hold
5,000
– – 0.04% 140
2024
Q1 		$410K Hold
5,000
– – 0.06% 126
2023
Q4 		$93K Buy
+5,000
New +$65.4K 0.02% 224

Other funds holding VKTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Nemes Rush Group's VKTX Position: Q3 2026 in Review

Nemes Rush Group held its Viking Therapeutics (VKTX) position steady in Q3 2026 at 5,165 shares worth $168K. The position accounts for 0.01% of the portfolio, ranked #222.

Nemes Rush Group first reported a position in VKTX in Q4 2023 and has held it in 12 quarters since. The position peaked at $410K in Q3 2024. 188 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

  • Nemes Rush Group held 5,165 shares of Viking Therapeutics worth $168K as of Q3 2026.
  • Nemes Rush Group left its Viking Therapeutics share count unchanged in Q3 2026.
  • Viking Therapeutics made up 0.01% of Nemes Rush Group's portfolio in Q3 2026, its #222 holding.
  • Nemes Rush Group first reported a position in Viking Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • Nemes Rush Group's Viking Therapeutics position peaked at $410K in Q3 2024.
  • 188 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on Nemes Rush Group's 13F filing for Q3 2026, filed 4 Nov 2026.